Efficacy and Safety of a Unani Formulation in the management of Gouty Arthritis
Phase 2
- Conditions
- Health Condition 1: M109- Gout, unspecified
- Registration Number
- CTRI/2024/08/072426
- Lead Sponsor
- FARHA LUQMA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Clinically diagnosed patient of Gout with raised Serum uric acid level beyond normal limit
Both sexes
Clinically stable Patient
Exclusion Criteria
Patient below 20 and above 65 years.
Gout with Diabetic Mellitus.
Pregnant women and lactating mother.
Severe illnesses of debilitated patients of cardiovascular system ,respiratory system, severe
renal or hepatic insufficiency, gastro- intestinal problems, nervous system and malignant
growth.
Any other type of arthritis such as Rheumatoid Arthritis, Osteoarthritis etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response to treatment will be assessed using the following parameter <br/ ><br>1-Reduction in uric acid <br/ ><br>2-Reduction in C. Reaction <br/ ><br>3-Improvement in Patients Global Assessement (PGA) based on VASTimepoint: 2week <br/ ><br>4 week <br/ ><br>6 week <br/ ><br>8 week
- Secondary Outcome Measures
Name Time Method Adverse effect <br/ ><br>kidney function test <br/ ><br>liver function test <br/ ><br>haemoglobinTimepoint: 8 week